ACS Medicinal Chemistry Letters

Papers
(The H4-Index of ACS Medicinal Chemistry Letters is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring113
Polybromo-1 Bromodomain Inhibitor Selectivity Is Mediated by a Unique Ligand-Binding Pocket110
Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols110
Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine71
Discovery of Selective Inhibitors of NaV1.7 Templated on Saxitoxin as Therapeutics for Pain58
Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport52
Issue Editorial Masthead49
Issue Publication Information47
Issue Publication Information45
Macrocyclic Oxindole Peptide Epoxyketones─A Comparative Study of Macrocyclic Inhibitors of the 20S Proteasome45
Cancer-Cell-Selective Targeting by Arylcyclopropylamine–Vorinostat Conjugates43
Synthesis of Monofluorinated 7-Hydroxycoumarin-3-Carboxamides as Cell-Permeable Fluorescent Molecular Probes41
Novel Tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine Compounds as Oxytocin Receptor Agonists for Treating Autism Spectrum Disorders39
Novel Heterocyclic Pyrimidine Derivatives as GSK3α Inhibitors39
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan39
Targeting the “Undruggable” Driver Protein, KRASG12D, as Potential Therapy in Prostate Cancer38
In This Issue, Volume 14, Issue 537
Call for Papers: Fungal Pathogens – Life Cycle, Infection, Host Immunity and Drug Discovery36
Novel Phosphorylpurinone Compounds for Treating Cancer35
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology33
Application of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders33
Clozapine as an E3 Ligand for PROTAC Technology32
Structure–Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD232
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach31
Virtual Screening-Guided Discovery of Small-Molecule CHI3L1 Inhibitors with Functional Activity in Glioblastoma Spheroids31
Design and Synthesis of a Structurally Stabilized B-Chain Antagonist Targeting Relaxin Family Peptide Receptor 3 (RXFP3)31
From Virtual Screens to Cellular Target Engagement: New Small Molecule Ligands for the Immune Checkpoint LAG-330
Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes30
Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer29
Discovery of a Novel sp3-Rich M1 Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping29
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation29
0.099061965942383